UNSPSC 51421601: Clobetasol

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28ClFO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ADN79D536H, chemically known as 21-chloro-9-fluoro-11b,17-dihydroxy-16a-methylpregna-1,4-diene-3,20-dione but generally known as clobetasol, which bears US NIH Compound Identifier 32797. European Medicines Agency schedules Clobetasol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06678MIG.

UNSPSC 51421601 Clobetasol, a Commodity code, shows limited recent activity aligned with its pharmaceutical scope. The single relevant recent state and local solicitation involves naloxone procurement — a pharmaceutical product acquired through emergency-response and public-health channels — rather than clobetasol specifically. State and local governments appear to use this code infrequently for pharmaceutical acquisition, and when they do, they pursue it through competitive bidding processes tied to health department or county community health operations rather than through specialized pharmaceutical vendors or standing agreements.

Seminole County, Florida issued an IFB (IFB60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 regarding direct-to-manufacturer prescription programs, but that solicitation addresses pharmacy benefit management and contracting strategy rather than specific pharmaceutical products. Geographic activity is sparse; the source identifies only Florida as an active jurisdiction under this code in recent months. Clobetasol-specific procurement does not appear in the recent-opportunities record, suggesting either minimal state and local demand for this particular topical corticosteroid or a prevalence of procurement under broader pharmaceutical supply contracts rather than discrete commodity codes.